Utah Medical Products (UTMD) 10-Q 6 Aug 21 2021 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2021	Aug. 05, 2021
Details
Entity Registrant Name	UTAH MEDICAL PRODUCTS INC
Entity Central Index Key	0000706698
Document Type	10-Q
Document Period End Date	Jun. 30, 2021
Current Fiscal Year End Date	--12-31
Trading Symbol	UTMD
Entity Tax Identification Number	87-0342734
Entity Common Stock, Shares Outstanding		3,646,611
Entity Filer Category	Non-accelerated Filer
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-12575
Entity Incorporation, State or Country Code	UT
Entity Address, Address Line One	7043 South 300 West
Entity Address, City or Town	Midvale
Entity Address, State or Province	UT
Entity Address, Postal Zip Code	84047
City Area Code	801
Local Phone Number	566-1200
Title of 12(b) Security	Common stock, $0.01 par value
Security Exchange Name	NASDAQ
Entity Interactive Data Current	Yes
Amendment Flag	false
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q2

UTAH MEDICAL PRODUCTS, INC. CON

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Current assets:
Cash & Investments	$ 59,506	$ 51,590
Accounts & other receivables, net	4,606	4,104
Inventories	6,118	6,222
Other current assets	357	346
Total current assets	70,587	62,262
Property and equipment, net	10,812	10,949
Operating lease - right-of-use assets, net	356	377
Goodwill	14,236	14,164
Other intangible assets	56,510	56,159
Other intangible assets - accumulated amortization	(35,707)	(32,166)
Other intangible assets, net	20,803	23,993
Total assets	116,794	111,745
Current liabilities:
Accounts payable	1,186	788
Accrued expenses	3,245	3,003
Total current liabilities	4,431	3,791
Deferred tax liability - Femcare IIA	2,355	2,151
Other long term liabilities	1,835	1,995
Operating lease liability	322	335
Deferred income taxes	486	651
Total liabilities	9,429	8,923
Stockholders' equity:
Common stock - $.01 par value; authorized - 50,000 shares; issued - June 30, 2021, 3,646 shares and December 31, 2020, 3,643 shares	36	36
Accumulated other comprehensive loss	(8,286)	(8,281)
Additional paid-in capital	289	115
Retained earnings	115,326	110,952
Total stockholders' equity	107,365	102,822
Total liabilities and stockholders' equity	$ 116,794	$ 111,745

UTAH MEDICAL PRODUCTS, INC. C_2

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED BALANCE SHEET - Parenthetical - $ / shares shares in Thousands	Jun. 30, 2021	Dec. 31, 2020
Details
Common Stock, Par or Stated Value Per Share	$ 0.01	$ 0.01
Common Stock, Shares Authorized	50,000	50,000
Common Stock, Shares, Issued	3,646	3,643
Common Stock, Shares, Outstanding	3,646	3,643

UTAH MEDICAL PRODUCTS, INC. C_3

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Details
Sales, net	$ 12,604	$ 8,787	$ 23,568	$ 19,689
Cost of goods sold	4,819	3,837	8,836	7,903
Gross profit	7,785	4,950	14,732	11,786
Operating expense
Selling, general and administrative	2,892	2,857	5,821	5,696
Research & development	128	116	259	250
Total operating expenses	3,020	2,973	6,080	5,946
Operating income	4,765	1,977	8,652	5,840
Other income	60	0	71	125
Income before provision for income taxes	4,825	1,977	8,723	5,965
Provision for income taxes	1,399	664	2,273	1,513
Net income	$ 3,426	$ 1,313	$ 6,450	$ 4,452
Earnings per common share (basic)	$ 0.94	$ 0.36	$ 1.77	$ 1.21
Earnings per common share (diluted)	$ 0.94	$ 0.36	$ 1.76	$ 1.21
Shares outstanding - basic	3,646	3,643	3,645	3,675
Shares outstanding - diluted	3,655	3,659	3,656	3,690
Other comprehensive income (loss):
Foreign currency translation net of taxes of $0 in all periods	$ 49	$ 522	$ (5)	$ (1,927)
Total comprehensive income	$ 3,475	$ 1,835	$ 6,445	$ 2,525

UTAH MEDICAL PRODUCTS, INC. C_4

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF INCOME - Parenthetical - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Details
Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax	$ 0	$ 0	$ 0	$ 0

UTAH MEDICAL PRODUCTS, INC. C_5

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED STATEMENT OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	Common Stock	Additional Paid-in Capital	Comprehensive Income	Retained Earnings	Total
Equity Balance, value at Dec. 31, 2019	$ 37	$ 18	$ (9,783)	$ 110,820	$ 101,092
Equity Balance, shares at Dec. 31, 2019	3,722
Common stock issued upon exercise of employee stock options	$ 0	48	0	0	48
Common stock issued upon exercise of employee stock options, shares	1
Stock option compensation expense	$ 0	23	0	0	23
Common stock purchased and retired	$ (1)	(89)	0	(6,336)	(6,426)
Common stock purchased and retired, shares	(80)
Foreign currency translation adjustment	$ 0	0	(2,449)	0	(2,449)
Common stock dividends	0	0	0	(1,042)	(1,042)
Net income	0	0	0	3,140	3,140
Equity Balance, value at Mar. 31, 2020	$ 36	0	(12,232)	106,582	94,386
Equity Balance, shares at Mar. 31, 2020	3,643
Equity Balance, value at Dec. 31, 2019	$ 37	18	(9,783)	110,820	101,092
Equity Balance, shares at Dec. 31, 2019	3,722
Foreign currency translation adjustment					(1,927)
Net income					4,452
Equity Balance, value at Jun. 30, 2020	$ 36	80	(11,710)	106,881	95,287
Equity Balance, shares at Jun. 30, 2020	3,643
Equity Balance, value at Mar. 31, 2020	$ 36	0	(12,232)	106,582	94,386
Equity Balance, shares at Mar. 31, 2020	3,643
Common stock issued upon exercise of employee stock options	$ 0	32	0	0	32
Common stock issued upon exercise of employee stock options, shares	1
Stock option compensation expense	$ 0	49	0	0	49
Foreign currency translation adjustment	0	0	522	0	522
Common stock dividends	0	0	0	(1,013)	(1,013)
Net income	0	0	0	1,313	1,313
Equity Balance, value at Jun. 30, 2020	$ 36	80	(11,710)	106,881	95,287
Equity Balance, shares at Jun. 30, 2020	3,643
Equity Balance, value at Dec. 31, 2020	$ 36	115	(8,281)	110,952	102,822
Equity Balance, shares at Dec. 31, 2020	3,643
Common stock issued upon exercise of employee stock options	$ 0	89	0	0	89
Common stock issued upon exercise of employee stock options, shares	3
Stock option compensation expense	$ 0	41	0	0	41
Foreign currency translation adjustment	0	0	(54)	0	(54)
Common stock dividends	0	0	0	(1,039)	(1,039)
Net income	0	0	0	3,024	3,024
Equity Balance, value at Mar. 31, 2021	$ 36	245	(8,335)	112,937	104,883
Equity Balance, shares at Mar. 31, 2021	3,646
Equity Balance, value at Dec. 31, 2020	$ 36	115	(8,281)	110,952	102,822
Equity Balance, shares at Dec. 31, 2020	3,643
Foreign currency translation adjustment					(5)
Net income					6,450
Equity Balance, value at Jun. 30, 2021	$ 36	289	(8,286)	115,326	107,365
Equity Balance, shares at Jun. 30, 2021	3,646
Equity Balance, value at Mar. 31, 2021	$ 36	245	(8,335)	112,937	104,883
Equity Balance, shares at Mar. 31, 2021	3,646
Common stock issued upon exercise of employee stock options	$ 0	3	0	0	3
Common stock issued upon exercise of employee stock options, shares	0
Stock option compensation expense	$ 0	41	0	0	41
Foreign currency translation adjustment	0	0	49	0	49
Common stock dividends	0	0	0	(1,037)	(1,037)
Net income	0	0	0	3,426	3,426
Equity Balance, value at Jun. 30, 2021	$ 36	$ 289	$ (8,286)	$ 115,326	$ 107,365
Equity Balance, shares at Jun. 30, 2021	3,646

UTAH MEDICAL PRODUCTS, INC. C_6

UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 6,450	$ 4,452
Adjustments to reconcile net income to net cash provided by operating activities
Depreciation	325	335
Amortization	3,335	3,242
Provision for (recovery of) losses on accounts receivable	8	(14)
Amortization of Right of Use Assets	21	19
Deferred income taxes	22	51
Stock-based compensation expense	82	72
Tax benefit attributable to exercise of stock options	5	7
Changes in operating assets and liabilities:
Accounts receivable and other receivables	(517)	903
Inventories	75	387
Prepaid expenses and other current assets	(14)	40
Accounts payable	399	(528)
Accrued expenses	34	385
Total adjustments	3,775	4,899
Net cash provided by operating activities	10,225	9,351
CASH FLOWS FROM INVESTING ACTIVITIES:
Property and equipment	(222)	(711)
Intangible assets	0	0
Net cash used in investing activities	(222)	(711)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock - options	92	79
Common stock purchased and retired	0	(6,426)
Payment of dividends	(2,077)	(2,077)
Net cash used in financing activities	(1,985)	(8,424)
Effect of exchange rate changes on cash	(102)	(651)
Net increase/(decrease) in cash and cash equivalents	7,916	(435)
Cash at beginning of period	51,590	42,787
Cash at end of period	59,506	42,352
Cash paid during the period for income taxes	2,279	786
Cash paid during the period for interest	$ 0	$ 0

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2021
Notes
Basis of Presentation	(1) The unaudited financial statements have been prepared in accordance with the instructions to Form 10-Q and do not include all of the information and note disclosures required by accounting principles generally accepted in the United States. These statements should be read in conjunction with the financial statements and notes included in the Utah Medical Products, Inc. ("UTMD" or "the Company") annual report on Form 10-K for the year ended December 31, 2020. In the opinion of management, the accompanying financial statements include all adjustments (consisting only of normal recurring adjustments) necessary to summarize fairly the Company's financial position and results of operations. Currency amounts are in thousands except per-share amounts and where noted.

New Accounting Pronouncements a

New Accounting Pronouncements and Changes in Accounting Principles	6 Months Ended
	Jun. 30, 2021
Notes
New Accounting Pronouncements and Changes in Accounting Principles	(2) Recent Accounting Standards. The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position or results of operations or cash flows, or will not apply to its operations.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2021
Notes
Inventories	(3) Inventories at June 30, 2021 and December 31, 2020 consisted of the following: June 30, 2021 December 31, 2020 Finished goods $ 1,088 $ 1,363 Work-in-process 1,263 1,375 Raw materials 3,767 3,484 Total $ 6,118 $ 6,222

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2021
Notes
Stock-Based Compensation	(4) Stock-Based Compensation. At June 30, 2021, the Company has stock-based employee compensation plans which authorize the grant of stock options to eligible employees and directors. The Company accounts for stock compensation under FASB Accounting Standards Codification (“ASC”) 718, Compensation - Stock Compensation

Warranty Reserve

Warranty Reserve	6 Months Ended
	Jun. 30, 2021
Notes
Warranty Reserve	(5) Warranty Reserve. The Company’s published warranty is: “UTMD warrants its products to conform in all material respects to all published product specifications in effect on the date of shipment, and to be free from defects in material and workmanship for a period of thirty (30) days for supplies, or twenty-four (24) months for equipment, from date of shipment. During the warranty period UTMD shall, at its option, replace any products shown to UTMD's reasonable satisfaction to be defective at no expense to the Purchaser or refund the purchase price.” UTMD maintains a warranty reserve to provide for estimated costs which are likely to occur. The amount of this reserve is adjusted, as required, to reflect its actual experience. Based on its analysis of historical warranty claims and its estimate that existing warranty obligations were immaterial, no warranty reserve was made at December 31, 2020 or June 30, 2021.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2021
Notes
Revenue Recognition	(6) Global 2Q 2021 revenues (USD) by product category: Domestic Outside US Total Obstetrics $ 946 $ 213 $ 1,159 Gynecology/Electrosurgery/Urology 2,873 2,801 5,674 Neonatal 1,303 339 1,642 Blood Pressure Monitoring and Accessories 2,901 1,228 4,129 Total $ 8,023 $ 4,581 $ 12,604 Global 1H 2021 revenues (USD) by product category: Domestic Outside US Total Obstetrics $ 1,850 $ 326 $ 2,176 Gynecology/Electrosurgery/Urology 5,486 5,316 10,802 Neonatal 2,476 753 3,229 Blood Pressure Monitoring and Accessories 4,993 2,368 7,361 Total $ 14,805 $ 8,763 $ 23,568

Leases

Leases	6 Months Ended
	Jun. 30, 2021
Notes
Leases	(7) Leases UTMD has operating leases for a portion of its parking lot at its Midvale facility and an automobile at its Ireland facility. The remaining lease term on the parking lot is 10 years and on the automobile is 6 months. There are no options to extend or terminate the leases. UTMD has no other leases yet to commence. As neither lease contains implicit rates, UTMD’s incremental borrowing rate, based on information available at adoption date, was used to determine the present value of the leases. The components of lease cost were as follows: Three Months Ended June 30, 2021 Operating Lease Cost ( in thousands $15 Right of Use Assets obtained in exchange for new operating lease Obligations - Other Information As of June 30, 2021 Weighted Average Remaining Lease Term – Operating Leases 10 years Weighted Average Discount Rate – Operating Leases 5.4% Operating lease liabilities/ payments ( in thousands Operating lease payments, 2021 $60 Operating lease payments, 2022 $45 Operating lease payments, 2023 $45 Operating lease payments, 2024 $45 Operating lease payments, 2025 $45 Thereafter $254 Reconciliation of operating lease liabilities/ payments to operating lease liabilities ( in thousands Total operating lease liabilities/ payments $464 Operating lease liabilities – current (included in Accrued Expenses) $34 Operating lease liabilities – long term $322 Present value adjustment $108 Maturities of lease liabilities were as follows: ( in thousands Year ending December 31, 2021 $41 2022 $27 2023 $29 2024 $30 2025 $32 Thereafter $218

CSI Distribution Agreement Purc

CSI Distribution Agreement Purchase Disclosure	6 Months Ended
	Jun. 30, 2021
Notes
CSI Distribution Agreement Purchase Disclosure	(8) Distribution Agreement Purchase. UTMD completed the purchase of exclusive U.S. distribution rights for the Filshie® Clip System from CooperSurgical, Inc. (CSI) on February 1, 2019. The $21,000 purchase price represented an identifiable intangible asset which is being straight-line amortized and recognized as part of G&A expenses over a remaining 2.33 year life as of June 30, 2021 of the prior CSI distribution agreement with Femcare.

Earnings Per Share

Earnings Per Share	6 Months Ended
	Jun. 30, 2021
Notes
Earnings Per Share	(9) Earnings Per Share. Basic earnings per share is calculated by dividing net income attributable to the common stockholders of the company by the weighted average number of common shares outstanding during the period. Diluted earnings per share is calculated by assuming the exercise of stock options at the closing price of stock on June 30, 2021. The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share: (in thousands) Three months ended Six months ended June 30, June 30, 2021 2020 2021 2020 Numerator Net income 3,426 1,313 6,450 4,452 Denominator Weighted average shares, basic 3,646 3,643 3,645 3,675 Dilutive effect of stock options 9 16 11 15 Diluted shares 3,655 3,659 3,656 3,690 Earnings per share, basic 0.94 0.36 1.77 1.21 Earnings per share, diluted 0.94 0.36 1.76 1.21

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2021
Notes
Subsequent Events	(10) Subsequent Events.

New Accounting Pronouncements_2

New Accounting Pronouncements and Changes in Accounting Principles: New Accounting Pronouncements, Policy (Policies)	6 Months Ended
	Jun. 30, 2021
Policies
New Accounting Pronouncements, Policy	The Company has determined that recently issued accounting standards will either have no material impact on its consolidated financial position or results of operations or cash flows, or will not apply to its operations.

Inventories_ Schedule of Invent

Inventories: Schedule of Inventory, Current (Tables)	6 Months Ended
	Jun. 30, 2021
Tables/Schedules
Schedule of Inventory, Current	June 30, 2021 December 31, 2020 Finished goods $ 1,088 $ 1,363 Work-in-process 1,263 1,375 Raw materials 3,767 3,484 Total $ 6,118 $ 6,222

Revenue Recognition_ Schedule O

Revenue Recognition: Schedule Of Revenues By Product Category (Tables)	6 Months Ended
	Jun. 30, 2021
Tables/Schedules
Schedule Of Revenues By Product Category	Domestic Outside US Total Obstetrics $ 946 $ 213 $ 1,159 Gynecology/Electrosurgery/Urology 2,873 2,801 5,674 Neonatal 1,303 339 1,642 Blood Pressure Monitoring and Accessories 2,901 1,228 4,129 Total $ 8,023 $ 4,581 $ 12,604 Global 1H 2021 revenues (USD) by product category: Domestic Outside US Total Obstetrics $ 1,850 $ 326 $ 2,176 Gynecology/Electrosurgery/Urology 5,486 5,316 10,802 Neonatal 2,476 753 3,229 Blood Pressure Monitoring and Accessories 4,993 2,368 7,361 Total $ 14,805 $ 8,763 $ 23,568

Leases_ Lease, Cost (Tables)

Leases: Lease, Cost (Tables)	6 Months Ended
	Jun. 30, 2021
Tables/Schedules
Lease, Cost	The components of lease cost were as follows: Three Months Ended June 30, 2021 Operating Lease Cost ( in thousands $15 Right of Use Assets obtained in exchange for new operating lease Obligations - Other Information As of June 30, 2021 Weighted Average Remaining Lease Term – Operating Leases 10 years Weighted Average Discount Rate – Operating Leases 5.4%

Leases_ Schedule of Future Mini

Leases: Schedule of Future Minimum Rental Payments for Operating Leases (Tables)	6 Months Ended
	Jun. 30, 2021
Tables/Schedules
Schedule of Future Minimum Rental Payments for Operating Leases	Operating lease liabilities/ payments ( in thousands Operating lease payments, 2021 $60 Operating lease payments, 2022 $45 Operating lease payments, 2023 $45 Operating lease payments, 2024 $45 Operating lease payments, 2025 $45 Thereafter $254

Leases_ Reconciliation of opera

Leases: Reconciliation of operating lease liabilities (Tables)	6 Months Ended
	Jun. 30, 2021
Tables/Schedules
Reconciliation of operating lease liabilities	Reconciliation of operating lease liabilities/ payments to operating lease liabilities ( in thousands Total operating lease liabilities/ payments $464 Operating lease liabilities – current (included in Accrued Expenses) $34 Operating lease liabilities – long term $322 Present value adjustment $108

Leases_ Lessee, Operating Lease

Leases: Lessee, Operating Lease, Liability, Maturity (Tables)	6 Months Ended
	Jun. 30, 2021
Tables/Schedules
Lessee, Operating Lease, Liability, Maturity	Maturities of lease liabilities were as follows: ( in thousands Year ending December 31, 2021 $41 2022 $27 2023 $29 2024 $30 2025 $32 Thereafter $218

Earnings Per Share_ Schedule of

Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Tables)	6 Months Ended
	Jun. 30, 2021
Tables/Schedules
Schedule of Earnings Per Share, Basic and Diluted	The following table reconciles the numerator and the denominator used to calculate basic and diluted earnings per share: (in thousands) Three months ended Six months ended June 30, June 30, 2021 2020 2021 2020 Numerator Net income 3,426 1,313 6,450 4,452 Denominator Weighted average shares, basic 3,646 3,643 3,645 3,675 Dilutive effect of stock options 9 16 11 15 Diluted shares 3,655 3,659 3,656 3,690 Earnings per share, basic 0.94 0.36 1.77 1.21 Earnings per share, diluted 0.94 0.36 1.76 1.21

Inventories_ Schedule of Inve_2

Inventories: Schedule of Inventory, Current (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Details
Finished goods	$ 1,088	$ 1,363
Work-in-process	1,263	1,375
Raw materials	3,767	3,484
Total	$ 6,118	$ 6,222

Stock-Based Compensation (Detai

Stock-Based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Details
Allocated Share-based Compensation Expense	$ 41	$ 49	$ 82	$ 72

Warranty Reserve (Details)

Warranty Reserve (Details) - USD ($)	Jun. 30, 2021	Dec. 31, 2020
Details
Standard and Extended Product Warranty Accrual	$ 0	$ 0

Revenue Recognition_ Schedule_2

Revenue Recognition: Schedule Of Revenues By Product Category (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Sales, net	$ 12,604	$ 8,787	$ 23,568	$ 19,689
Obstetrics
Sales, net	1,159		2,176
Gynecology/Electrosurgery/Urology
Sales, net	5,674		10,802
Neonatal
Sales, net	1,642		3,229
Blood Pressure Monitoring and Accessories
Sales, net	4,129		7,361
DomesticUsMember
Sales, net	8,023		14,805
DomesticUsMember | Obstetrics
Sales, net	946		1,850
DomesticUsMember | Gynecology/Electrosurgery/Urology
Sales, net	2,873		5,486
DomesticUsMember | Neonatal
Sales, net	1,303		2,476
DomesticUsMember | Blood Pressure Monitoring and Accessories
Sales, net	2,901		4,993
OutsideUsMember
Sales, net	4,581		8,763
OutsideUsMember | Obstetrics
Sales, net	213		326
OutsideUsMember | Gynecology/Electrosurgery/Urology
Sales, net	2,801		5,316
OutsideUsMember | Neonatal
Sales, net	339		753
OutsideUsMember | Blood Pressure Monitoring and Accessories
Sales, net	$ 1,228		$ 2,368

Leases (Details)

Leases (Details)	Jun. 30, 2021
Details
Lessee Operating Lease for Parking Lot Term of Contract	10 years
Lessee Operating Lease for Automobile Term of Contract	6 months

Leases_ Lease, Cost (Details)

Leases: Lease, Cost (Details) $ in Thousands	3 Months Ended
	Jun. 30, 2021USD ($)
Details
Operating Lease, Cost	$ 15
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability	$ 0
Operating Lease, Weighted Average Remaining Lease Term	10 years
Operating Lease, Weighted Average Discount Rate, Percent	5.40%

Leases_ Schedule of Future Mi_2

Leases: Schedule of Future Minimum Rental Payments for Operating Leases (Details) $ in Thousands	Dec. 31, 2020USD ($)
Details
Operating Leases, Future Minimum Payments Due, Next Twelve Months	$ 60
Operating Leases, Future Minimum Payments, Due in Two Years	45
Operating Leases, Future Minimum Payments, Due in Three Years	45
Operating Leases, Future Minimum Payments, Due in Four Years	45
Operating Leases, Future Minimum Payments, Due in Five Years	45
Operating Leases, Future Minimum Payments, Due Thereafter	$ 254

Leases_ Reconciliation of ope_2

Leases: Reconciliation of operating lease liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Details
Lessee, Operating Lease, Liability, to be Paid	$ 464
Operating Lease, Liability, Current	34
Operating lease liability	322	$ 335
Lessee, Operating Lease, Liability, Undiscounted Excess Amount	$ 108

Leases_ Lessee, Operating Lea_2

Leases: Lessee, Operating Lease, Liability, Maturity (Details) $ in Thousands	Dec. 31, 2020USD ($)
Details
Lessee, Operating Lease, Liability, to be Paid, Year One	$ 41
Lessee, Operating Lease, Liability, to be Paid, Year Two	27
Lessee, Operating Lease, Liability, to be Paid, Year Three	29
Lessee, Operating Lease, Liability, to be Paid, Year Four	30
Lessee, Operating Lease, Liability, to be Paid, Year Five	32
Lessee, Operating Lease, Liability, to be Paid, after Year Five	$ 218

CSI Distribution Agreement Pu_2

CSI Distribution Agreement Purchase Disclosure (Details) - CooperSurgical Inc $ in Thousands	Jun. 30, 2021	Mar. 31, 2019USD ($)
Finite-lived Intangible Assets Acquired		$ 21,000
Remaining years of exclusive U.S. distribution rights for Femcare's Filshie Clip System	2.33

Earnings Per Share_ Schedule _2

Earnings Per Share: Schedule of Earnings Per Share, Basic and Diluted (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2020	Mar. 31, 2020	Jun. 30, 2021	Jun. 30, 2020
Details
Net income	$ 3,426	$ 3,024	$ 1,313	$ 3,140	$ 6,450	$ 4,452
Weighted average shares, basic	3,646		3,643		3,645	3,675
Dilutive effect of stock options	9		16		11	15
Diluted shares	3,655		3,659		3,656	3,690
Earnings per share, basic	$ 0.94		$ 0.36		$ 1.77	$ 1.21
Earnings per share, diluted	$ 0.94		$ 0.36		$ 1.76	$ 1.21